Lifemel Honey to Reduce Leucopenia During Chemotherapy

Rambam Health Care Campus

Status and phase: Unknown; Phase 2

Conditions: Breast Cancer

Treatments: Behavioral: Lifemel honey intake every day

Study type: Interventional

Funder types: Other

Identifiers

NCT00243165

LifemelCTIL

Details and patient eligibility

About

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

Enrollment: 60 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• breast cancer patient treated with adjuvant chemotherapy
• PS = 2 or less

Exclusion criteria

• none

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind